# A Phase II Study To Evaluate the Efficacy And Safety Of HRS-1301 In Participants With Dyslipidemia

> **NCT07229937** · PHASE2 · RECRUITING · sponsor: **Shandong Suncadia Medicine Co., Ltd.** · enrollment: 189 (estimated)

## Conditions studied

- Hyperlipidemia

## Interventions

- **DRUG:** HRS-1301
- **DRUG:** HRS-1301
- **DRUG:** HRS-1301
- **DRUG:** HRS-1301
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07229937
- **Lead sponsor:** Shandong Suncadia Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-25
- **Primary completion:** 2026-08
- **Final completion:** 2026-08
- **Target enrollment:** 189 (ESTIMATED)
- **Last updated:** 2025-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07229937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07229937, "A Phase II Study To Evaluate the Efficacy And Safety Of HRS-1301 In Participants With Dyslipidemia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07229937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*